Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INCYTE CORPORATION

(INCY)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe BZX - 12/07 12:48:39 pm
66.965 USD   +3.01%
11/19BMO Capital Starts Incyte at Market Perform With $75 Price Target
MT
11/18Novartis Said Considering Takeover in Biotech Sector
MT
11/09Incyte to Present at Upcoming Investor Conference
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

GvHD Hub in Q3: Boosting levels of knowledge in the graft-versus-host disease setting

10/15/2021 | 06:47am EST

Founded in partnership with the European LeukemiaNet (ELN) and brought to you by Scientific Education Support (SES), the GvHD Hub provides up-to-date, unbiased resources for healthcare professionals in the graft-versus-host disease (GvHD) setting.

The GvHD Hub remains dedicated to bringing you the latest information regarding COVID-19 and its implications in patients undergoing hematopoietic stem cell transplantation, as well as keeping on top of the unmet medical needs in the field.

Speaking about the impact the hub has had this year, Mia Hill, IME Director at Scientific Education Support, said:

"This quarter, the GvHD Hub ran a successful steering committee meeting centered around the educational needs in the GvHD setting and how to best represent them on the GvHD Hub. The GvHD Hub also virtually attended two major congresses: the 9th Annual Meeting of the Society of Hematologic Oncology (SOHO) and 4th Annual Meeting of the International Academy for Clinical Hematology (IACH). We provided live session coverage of these meetings, establishing an online presence to facilitate the dissemination of key updates and breakthroughs in GvHD, worldwide. Our social coverage generated over 13,000 impressions and over 200 new website users, which demonstrates the impact our coverage has on the GvHD community."

The GvHD Hub initiative is financially supported by Incyte (Silver), Novartis (Silver), Syndax (Bronze), and Kadmon (Contributor); we remain grateful for their invaluable support.

ENDS

For more information on the GvHD Hub, please visit gvhdhub.com.

For media enquiries or to explore collaboration opportunities, please contact: secretariat@scientificeducationsupport.com

or Barry.Connolly@scientificeducationsupport.com.

NOTES TO EDITOR

About graft-versus-host disease (GvHD)

GvHD is a common complication of allogeneic hematopoietic stem cell transplantation and is a major cause of posttransplant mortality and morbidity. It is caused by immune incompatibility between the graft (donor) and recipient tissues. The graft cells recognize the recipient tissues as foreign and mount an immune response against them.

About the GvHD Hub

The GvHD Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education on GvHD. Our aim is to enhance knowledge of GvHD through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management.

The GvHD Hub enables time-stretched HCPs to easily access impactful information that expedites learning and empowers their treatment decisions. Informed by patients, curated by world leaders, and endorsed by expert societies, the GvHD Hub supports HCPs worldwide.

The GvHD Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.

The GvHD Hub is guided by an international steering committee of world-leading experts in the field of GvHD and is run in partnership with the European LeukemiaNet.

GvHD Hub supporters

Funding for our hubs is made possible through financial support from the pharmaceutical industry. All content is developed by SES in collaboration with an expert steering committee. All content is independent, and the educational supporters are allowed no influence on the content.

- Incyte

- Novartis

- Syndax

- Kadmon

If you are interested in becoming an GvHD supporter, please contact secretariat@scientificeducationsupport.com.

About Scientific Education Support (SES)

SES is a medical education company with projects such as community physician education through our therapy hubs, community awareness and education through our 'Know' education initiatives, and academic researcher education through Entrepreneurs in Clinical Academia (ECA) programs.

SES already has a portfolio of successful websites supporting the advancement of medical education in the field of hemato-oncology, including the ALL Hub, AML Hub, Lymphoma Hub, MDS Hub, Multiple Myeloma Hub, and MPN Hub.

About the European LeukemiaNet

The European LeukemiaNet cooperates with 220 participating centers in 44 countries, with more than 1,000 researchers and clinicians. The objective is to integrate about 120 leading leukemia trial groups (CML, AML, ALL, CLL, MDS, MPN), their interdisciplinary partner groups (diagnostics, treatment research, registry, guidelines), industry, and SMEs across Europe to form a network promoting cooperative research for curing leukemia.

Distributed by https://pressat.co.uk/

.

(C) 2021 M2 COMMUNICATIONS, source M2 PressWIRE

All news about INCYTE CORPORATION
11/19BMO Capital Starts Incyte at Market Perform With $75 Price Target
MT
11/18Novartis Said Considering Takeover in Biotech Sector
MT
11/09Incyte to Present at Upcoming Investor Conference
BU
11/08First Patient Dosed in SELECT-AML-1 Trial of Tamibarotene and in Dose Confirmation Stud..
AQ
11/04JMP Securities Adjusts Price Target on Incyte to $108 from $124, Keeps Market Outperfor..
MT
11/04More than 35 Abstracts from Incyte's Oncology Portfolio Accepted for Presentation at th..
BU
11/04SEC Brings Insider Trading Out Of The Shadows
AQ
11/03Oppenheimer Adjusts Price Target on Incyte to $109 from $110; Keeps Outperform Rating
MT
11/02INCYTE CORP Management's Discussion and Analysis of Financial Condition and Results of..
AQ
11/02Corporate Statement Regarding Opzelura™ (ruxolitinib) Cream - Form 8-K
PU
More news
Analyst Recommendations on INCYTE CORPORATION
More recommendations
Financials (USD)
Sales 2021 2 928 M - -
Net income 2021 525 M - -
Net cash 2021 2 043 M - -
P/E ratio 2021 27,7x
Yield 2021 -
Capitalization 14 360 M 14 360 M -
EV / Sales 2021 4,21x
EV / Sales 2022 3,33x
Nbr of Employees 1 773
Free-Float 98,5%
Chart INCYTE CORPORATION
Duration : Period :
Incyte Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INCYTE CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 65,01 $
Average target price 94,47 $
Spread / Average Target 45,3%
EPS Revisions
Managers and Directors
Herve Hoppenot Chairman, President & Chief Executive Officer
Christiana Stamoulis Chief Financial Officer & Executive Vice President
Steven H. Stein Chief Medical Officer & Executive Vice President
Dashyant Dhanak Chief Scientific Officer & Executive VP
Julian Charles Baker Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
INCYTE CORPORATION-23.40%14 360
MODERNA, INC.153.98%107 578
LONZA GROUP AG25.98%56 683
IQVIA HOLDINGS INC.46.84%50 262
SEAGEN INC.-16.63%26 699
CELLTRION, INC.-42.48%23 888